Back to first-pass browser

First-pass extracted concept

P-selectin-targeting biomaterials

Candidate: concept label1 source documents5 linked claims
Jump to explainersJump to evidenceJump to sourcesJump to claims
Live refresh every 5sNext refresh in 5s

Extracted Explainers

What the tool is doing

This label covers biomaterial strategies that target P-selectin for drug delivery in cancer, thrombosis, and inflammatory disorders. The abstract states these systems exploit P-selectin affinity and disease-associated surface expression.

Source 1DOIPubMed

Resources required

These approaches require a P-selectin-binding material class such as polysaccharide derivatives, glycomimetics, antibodies, peptides, aptamers, or cell-mimetic carriers. They also require a disease context or external stimulus in which P-selectin is present on cell surfaces.

Source 1DOIPubMed

What problem it solves

They aim to improve precision delivery to pathological tissues with elevated P-selectin and limited healthy-tissue expression. This is presented as a route to enhanced therapeutic efficacy.

Source 1DOIPubMed

What it does not solve

The abstract explicitly notes unresolved challenges in biodistribution optimization, scalability, and clinical translation.

Source 1DOIPubMed

Alternatives

The abstract contrasts multiple targeting material classes within the P-selectin-targeting space, including polysaccharide derivatives, glycomimetics, antibodies, peptides, aptamers, and cell-mimetic carriers.

Source 1DOIPubMed

Evidence Snippets

We discuss diverse P-selectin-targeting biomaterials, including polysaccharide derivatives, glycomimetics, antibodies, peptides, aptamers, and cell-mimetic carriers
Evidence 1Source 1DOIPubMedprovenance

Supporting Sources

Linked Claims

Claim 1application scopesupports2026Source 1DOIPubMed

The review discusses multiple classes of P-selectin-targeting biomaterials, including polysaccharide derivatives, glycomimetics, antibodies, peptides, aptamers, and cell-mimetic carriers.

Quoted textsource-backed
We discuss diverse P-selectin-targeting biomaterials, including polysaccharide derivatives, glycomimetics, antibodies, peptides, aptamers, and cell-mimetic carriers
Claim 2limitationsupports2026Source 1DOIPubMed

Biodistribution optimization, scalability, and clinical translation remain challenges for P-selectin-based delivery systems.

Quoted textsource-backed
Challenges such as biodistribution optimization, scalability, and clinical translation are critically analyzed
Claim 3mechanistic rationalesupports2026Source 1DOIPubMed

Rapid translocation of P-selectin to cell surfaces upon injury or external stimuli, together with minimal expression in healthy tissues, enables precise therapeutic targeting.

Quoted textsource-backed
As a dynamic and disease-specific biomarker, its rapid translocation to cell surfaces upon injury or external stimuli, coupled with minimal expression in healthy tissues, enables precise therapeutic targeting.
Claim 4performance summarysupports2026Source 1DOIPubMed

Advanced P-selectin-targeted delivery systems are described as demonstrating enhanced efficacy across cancer, thrombotic, atherosclerotic, ischemia-reperfusion, and rheumatoid arthritis applications.

Quoted textsource-backed
Advanced delivery systems leveraging these materials demonstrate enhanced efficacy in treating cancers, thrombotic disorders, atherosclerosis, ischemia-reperfusion injuries, rheumatoid arthritis
Claim 5target rationalesupports2026Source 1DOIPubMed

P-selectin is presented as a promising biomarker for targeted drug delivery in pathological conditions including inflammation, thrombosis, and cancer.

Quoted textsource-backed
P-selectin, a cell adhesion molecule overexpressed in pathological conditions such as inflammation, thrombosis, and cancer, has emerged as a promising biomarker for targeted drug delivery.